Global Opioid-induced Constipation Market Size, Status and Forecast 2021-2027

オピオイド誘発性便秘の世界市場規模・現状・予測2021年-2027年

◆タイトル:Global Opioid-induced Constipation Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR4282
◆調査・発行会社:QYResearch
◆発行日:2021年4月
◆ページ数:126
◆レポート形式:(印刷可能)PDF / 英語
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル、主要地域
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥429,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥643,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥858,000見積依頼/購入/質問フォーム
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常2日~3日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearchの日本における正規販売代理店です。

【レポートの概要】

本調査資料では、オピオイド誘発性便秘の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(固体、液体)、用途別市場規模(ドラッグストア、病院、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・オピオイド誘発性便秘の市場動向
・企業の競争状況、市場シェア
・オピオイド誘発性便秘の種類別市場規模(固体、液体)
・オピオイド誘発性便秘の用途別市場規模(ドラッグストア、病院、その他)
・オピオイド誘発性便秘の北米市場規模2016-2027(アメリカ、カナダ)
・オピオイド誘発性便秘の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・オピオイド誘発性便秘のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・オピオイド誘発性便秘の中南米市場規模2016-2027(メキシコ、ブラジル)
・オピオイド誘発性便秘の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(AstraZeneca、Takeda Pharmaceutical、Bausch Health、Abbott、Bayer、Boehringer Ingelheim、C.B. Fleet、Cosmo Pharmaceuticals、Daewoong、Daiichi Sankyo、GlaxoSmithKline、Ironwood Pharmaceuticals、Johnson and Johnson、Merck、Mundipharma、Nektar Therapeutics、Pfizer、Progenics Pharmaceuticals、Shionogi、SLA Pharma、Sucampo、Synergy Pharmaceuticals、Theravance)
・結論

Market Analysis and Insights: Global Opioid-induced Constipation Market
The global Opioid-induced Constipation market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Opioid-induced Constipation market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Opioid-induced Constipation market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Opioid-induced Constipation market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Opioid-induced Constipation market.

Global Opioid-induced Constipation Scope and Market Size
Opioid-induced Constipation market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Opioid-induced Constipation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Solid
Liquid

Segment by Application
Drugstore
Hospital
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Takeda Pharmaceutical
Bausch Health
Abbott
Bayer
Boehringer Ingelheim
C.B. Fleet
Cosmo Pharmaceuticals
Daewoong
Abbott
Bayer
Ironwood Pharmaceuticals
Johnson and Johnson
Merck
Mundipharma
Nektar Therapeutics
Pfizer
Progenics Pharmaceuticals
Shionogi
SLA Pharma
Sucampo

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Opioid-induced Constipation Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Solid
1.2.3 Liquid
1.3 Market by Application
1.3.1 Global Opioid-induced Constipation Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Drugstore
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Opioid-induced Constipation Market Perspective (2016-2027)
2.2 Opioid-induced Constipation Growth Trends by Regions
2.2.1 Opioid-induced Constipation Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Opioid-induced Constipation Historic Market Share by Regions (2016-2021)
2.2.3 Opioid-induced Constipation Forecasted Market Size by Regions (2022-2027)
2.3 Opioid-induced Constipation Industry Dynamic
2.3.1 Opioid-induced Constipation Market Trends
2.3.2 Opioid-induced Constipation Market Drivers
2.3.3 Opioid-induced Constipation Market Challenges
2.3.4 Opioid-induced Constipation Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Opioid-induced Constipation Players by Revenue
3.1.1 Global Top Opioid-induced Constipation Players by Revenue (2016-2021)
3.1.2 Global Opioid-induced Constipation Revenue Market Share by Players (2016-2021)
3.2 Global Opioid-induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Opioid-induced Constipation Revenue
3.4 Global Opioid-induced Constipation Market Concentration Ratio
3.4.1 Global Opioid-induced Constipation Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Opioid-induced Constipation Revenue in 2020
3.5 Opioid-induced Constipation Key Players Head office and Area Served
3.6 Key Players Opioid-induced Constipation Product Solution and Service
3.7 Date of Enter into Opioid-induced Constipation Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Opioid-induced Constipation Breakdown Data by Type
4.1 Global Opioid-induced Constipation Historic Market Size by Type (2016-2021)
4.2 Global Opioid-induced Constipation Forecasted Market Size by Type (2022-2027)

5 Opioid-induced Constipation Breakdown Data by Application
5.1 Global Opioid-induced Constipation Historic Market Size by Application (2016-2021)
5.2 Global Opioid-induced Constipation Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Opioid-induced Constipation Market Size (2016-2027)
6.2 North America Opioid-induced Constipation Market Size by Type
6.2.1 North America Opioid-induced Constipation Market Size by Type (2016-2021)
6.2.2 North America Opioid-induced Constipation Market Size by Type (2022-2027)
6.2.3 North America Opioid-induced Constipation Market Size by Type (2016-2027)
6.3 North America Opioid-induced Constipation Market Size by Application
6.3.1 North America Opioid-induced Constipation Market Size by Application (2016-2021)
6.3.2 North America Opioid-induced Constipation Market Size by Application (2022-2027)
6.3.3 North America Opioid-induced Constipation Market Size by Application (2016-2027)
6.4 North America Opioid-induced Constipation Market Size by Country
6.4.1 North America Opioid-induced Constipation Market Size by Country (2016-2021)
6.4.2 North America Opioid-induced Constipation Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Opioid-induced Constipation Market Size (2016-2027)
7.2 Europe Opioid-induced Constipation Market Size by Type
7.2.1 Europe Opioid-induced Constipation Market Size by Type (2016-2021)
7.2.2 Europe Opioid-induced Constipation Market Size by Type (2022-2027)
7.2.3 Europe Opioid-induced Constipation Market Size by Type (2016-2027)
7.3 Europe Opioid-induced Constipation Market Size by Application
7.3.1 Europe Opioid-induced Constipation Market Size by Application (2016-2021)
7.3.2 Europe Opioid-induced Constipation Market Size by Application (2022-2027)
7.3.3 Europe Opioid-induced Constipation Market Size by Application (2016-2027)
7.4 Europe Opioid-induced Constipation Market Size by Country
7.4.1 Europe Opioid-induced Constipation Market Size by Country (2016-2021)
7.4.2 Europe Opioid-induced Constipation Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Opioid-induced Constipation Market Size (2016-2027)
8.2 Asia-Pacific Opioid-induced Constipation Market Size by Type
8.2.1 Asia-Pacific Opioid-induced Constipation Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Opioid-induced Constipation Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Opioid-induced Constipation Market Size by Type (2016-2027)
8.3 Asia-Pacific Opioid-induced Constipation Market Size by Application
8.3.1 Asia-Pacific Opioid-induced Constipation Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Opioid-induced Constipation Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Opioid-induced Constipation Market Size by Application (2016-2027)
8.4 Asia-Pacific Opioid-induced Constipation Market Size by Region
8.4.1 Asia-Pacific Opioid-induced Constipation Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Opioid-induced Constipation Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Opioid-induced Constipation Market Size (2016-2027)
9.2 Latin America Opioid-induced Constipation Market Size by Type
9.2.1 Latin America Opioid-induced Constipation Market Size by Type (2016-2021)
9.2.2 Latin America Opioid-induced Constipation Market Size by Type (2022-2027)
9.2.3 Latin America Opioid-induced Constipation Market Size by Type (2016-2027)
9.3 Latin America Opioid-induced Constipation Market Size by Application
9.3.1 Latin America Opioid-induced Constipation Market Size by Application (2016-2021)
9.3.2 Latin America Opioid-induced Constipation Market Size by Application (2022-2027)
9.3.3 Latin America Opioid-induced Constipation Market Size by Application (2016-2027)
9.4 Latin America Opioid-induced Constipation Market Size by Country
9.4.1 Latin America Opioid-induced Constipation Market Size by Country (2016-2021)
9.4.2 Latin America Opioid-induced Constipation Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Opioid-induced Constipation Market Size (2016-2027)
10.2 Middle East & Africa Opioid-induced Constipation Market Size by Type
10.2.1 Middle East & Africa Opioid-induced Constipation Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Opioid-induced Constipation Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Opioid-induced Constipation Market Size by Type (2016-2027)
10.3 Middle East & Africa Opioid-induced Constipation Market Size by Application
10.3.1 Middle East & Africa Opioid-induced Constipation Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Opioid-induced Constipation Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Opioid-induced Constipation Market Size by Application (2016-2027)
10.4 Middle East & Africa Opioid-induced Constipation Market Size by Country
10.4.1 Middle East & Africa Opioid-induced Constipation Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Opioid-induced Constipation Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Opioid-induced Constipation Introduction
11.1.4 AstraZeneca Revenue in Opioid-induced Constipation Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Takeda Pharmaceutical
11.2.1 Takeda Pharmaceutical Company Details
11.2.2 Takeda Pharmaceutical Business Overview
11.2.3 Takeda Pharmaceutical Opioid-induced Constipation Introduction
11.2.4 Takeda Pharmaceutical Revenue in Opioid-induced Constipation Business (2016-2021)
11.2.5 Takeda Pharmaceutical Recent Development
11.3 Bausch Health
11.3.1 Bausch Health Company Details
11.3.2 Bausch Health Business Overview
11.3.3 Bausch Health Opioid-induced Constipation Introduction
11.3.4 Bausch Health Revenue in Opioid-induced Constipation Business (2016-2021)
11.3.5 Bausch Health Recent Development
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Abbott Business Overview
11.4.3 Abbott Opioid-induced Constipation Introduction
11.4.4 Abbott Revenue in Opioid-induced Constipation Business (2016-2021)
11.4.5 Abbott Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Opioid-induced Constipation Introduction
11.5.4 Bayer Revenue in Opioid-induced Constipation Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Opioid-induced Constipation Introduction
11.6.4 Boehringer Ingelheim Revenue in Opioid-induced Constipation Business (2016-2021)
11.6.5 Boehringer Ingelheim Recent Development
11.7 C.B. Fleet
11.7.1 C.B. Fleet Company Details
11.7.2 C.B. Fleet Business Overview
11.7.3 C.B. Fleet Opioid-induced Constipation Introduction
11.7.4 C.B. Fleet Revenue in Opioid-induced Constipation Business (2016-2021)
11.7.5 C.B. Fleet Recent Development
11.8 Cosmo Pharmaceuticals
11.8.1 Cosmo Pharmaceuticals Company Details
11.8.2 Cosmo Pharmaceuticals Business Overview
11.8.3 Cosmo Pharmaceuticals Opioid-induced Constipation Introduction
11.8.4 Cosmo Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021)
11.8.5 Cosmo Pharmaceuticals Recent Development
11.9 Daewoong
11.9.1 Daewoong Company Details
11.9.2 Daewoong Business Overview
11.9.3 Daewoong Opioid-induced Constipation Introduction
11.9.4 Daewoong Revenue in Opioid-induced Constipation Business (2016-2021)
11.9.5 Daewoong Recent Development
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Details
11.10.2 Daiichi Sankyo Business Overview
11.10.3 Daiichi Sankyo Opioid-induced Constipation Introduction
11.10.4 Daiichi Sankyo Revenue in Opioid-induced Constipation Business (2016-2021)
11.10.5 Daiichi Sankyo Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Opioid-induced Constipation Introduction
11.11.4 GlaxoSmithKline Revenue in Opioid-induced Constipation Business (2016-2021)
11.11.5 GlaxoSmithKline Recent Development
11.12 Ironwood Pharmaceuticals
11.12.1 Ironwood Pharmaceuticals Company Details
11.12.2 Ironwood Pharmaceuticals Business Overview
11.12.3 Ironwood Pharmaceuticals Opioid-induced Constipation Introduction
11.12.4 Ironwood Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021)
11.12.5 Ironwood Pharmaceuticals Recent Development
11.13 Johnson and Johnson
11.13.1 Johnson and Johnson Company Details
11.13.2 Johnson and Johnson Business Overview
11.13.3 Johnson and Johnson Opioid-induced Constipation Introduction
11.13.4 Johnson and Johnson Revenue in Opioid-induced Constipation Business (2016-2021)
11.13.5 Johnson and Johnson Recent Development
11.14 Merck
11.14.1 Merck Company Details
11.14.2 Merck Business Overview
11.14.3 Merck Opioid-induced Constipation Introduction
11.14.4 Merck Revenue in Opioid-induced Constipation Business (2016-2021)
11.14.5 Merck Recent Development
11.15 Mundipharma
11.15.1 Mundipharma Company Details
11.15.2 Mundipharma Business Overview
11.15.3 Mundipharma Opioid-induced Constipation Introduction
11.15.4 Mundipharma Revenue in Opioid-induced Constipation Business (2016-2021)
11.15.5 Mundipharma Recent Development
11.16 Nektar Therapeutics
11.16.1 Nektar Therapeutics Company Details
11.16.2 Nektar Therapeutics Business Overview
11.16.3 Nektar Therapeutics Opioid-induced Constipation Introduction
11.16.4 Nektar Therapeutics Revenue in Opioid-induced Constipation Business (2016-2021)
11.16.5 Nektar Therapeutics Recent Development
11.17 Pfizer
11.17.1 Pfizer Company Details
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Opioid-induced Constipation Introduction
11.17.4 Pfizer Revenue in Opioid-induced Constipation Business (2016-2021)
11.17.5 Pfizer Recent Development
11.18 Progenics Pharmaceuticals
11.18.1 Progenics Pharmaceuticals Company Details
11.18.2 Progenics Pharmaceuticals Business Overview
11.18.3 Progenics Pharmaceuticals Opioid-induced Constipation Introduction
11.18.4 Progenics Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021)
11.18.5 Progenics Pharmaceuticals Recent Development
11.18 Shionogi
.1 Shionogi Company Details
.2 Shionogi Business Overview
.3 Shionogi Opioid-induced Constipation Introduction
.4 Shionogi Revenue in Opioid-induced Constipation Business (2016-2021)
.5 Shionogi Recent Development
11.20 SLA Pharma
11.20.1 SLA Pharma Company Details
11.20.2 SLA Pharma Business Overview
11.20.3 SLA Pharma Opioid-induced Constipation Introduction
11.20.4 SLA Pharma Revenue in Opioid-induced Constipation Business (2016-2021)
11.20.5 SLA Pharma Recent Development
11.21 Sucampo
11.21.1 Sucampo Company Details
11.21.2 Sucampo Business Overview
11.21.3 Sucampo Opioid-induced Constipation Introduction
11.21.4 Sucampo Revenue in Opioid-induced Constipation Business (2016-2021)
11.21.5 Sucampo Recent Development
11.22 Synergy Pharmaceuticals
11.22.1 Synergy Pharmaceuticals Company Details
11.22.2 Synergy Pharmaceuticals Business Overview
11.22.3 Synergy Pharmaceuticals Opioid-induced Constipation Introduction
11.22.4 Synergy Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021)
11.22.5 Synergy Pharmaceuticals Recent Development
11.23 Theravance
11.23.1 Theravance Company Details
11.23.2 Theravance Business Overview
11.23.3 Theravance Opioid-induced Constipation Introduction
11.23.4 Theravance Revenue in Opioid-induced Constipation Business (2016-2021)
11.23.5 Theravance Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Opioid-induced Constipation Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Solid
Table 3. Key Players of Liquid
Table 4. Global Opioid-induced Constipation Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Opioid-induced Constipation Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Opioid-induced Constipation Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Opioid-induced Constipation Market Share by Regions (2016-2021)
Table 8. Global Opioid-induced Constipation Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Opioid-induced Constipation Market Share by Regions (2022-2027)
Table 10. Opioid-induced Constipation Market Trends
Table 11. Opioid-induced Constipation Market Drivers
Table 12. Opioid-induced Constipation Market Challenges
Table 13. Opioid-induced Constipation Market Restraints
Table 14. Global Opioid-induced Constipation Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Opioid-induced Constipation Market Share by Players (2016-2021)
Table 16. Global Top Opioid-induced Constipation Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-induced Constipation as of 2020)
Table 17. Ranking of Global Top Opioid-induced Constipation Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Opioid-induced Constipation Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Opioid-induced Constipation Product Solution and Service
Table 21. Date of Enter into Opioid-induced Constipation Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Opioid-induced Constipation Revenue Market Share by Type (2016-2021)
Table 25. Global Opioid-induced Constipation Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Opioid-induced Constipation Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Opioid-induced Constipation Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Opioid-induced Constipation Revenue Market Share by Application (2016-2021)
Table 29. Global Opioid-induced Constipation Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Opioid-induced Constipation Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Opioid-induced Constipation Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Opioid-induced Constipation Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million)
Table 61. AstraZeneca Company Details
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Opioid-induced Constipation Product
Table 64. AstraZeneca Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 65. AstraZeneca Recent Development
Table 66. Takeda Pharmaceutical Company Details
Table 67. Takeda Pharmaceutical Business Overview
Table 68. Takeda Pharmaceutical Opioid-induced Constipation Product
Table 69. Takeda Pharmaceutical Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 70. Takeda Pharmaceutical Recent Development
Table 71. Bausch Health Company Details
Table 72. Bausch Health Business Overview
Table 73. Bausch Health Opioid-induced Constipation Product
Table 74. Bausch Health Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 75. Bausch Health Recent Development
Table 76. Abbott Company Details
Table 77. Abbott Business Overview
Table 78. Abbott Opioid-induced Constipation Product
Table 79. Abbott Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 80. Abbott Recent Development
Table 81. Bayer Company Details
Table 82. Bayer Business Overview
Table 83. Bayer Opioid-induced Constipation Product
Table 84. Bayer Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 85. Bayer Recent Development
Table 86. Boehringer Ingelheim Company Details
Table 87. Boehringer Ingelheim Business Overview
Table 88. Boehringer Ingelheim Opioid-induced Constipation Product
Table 89. Boehringer Ingelheim Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 90. Boehringer Ingelheim Recent Development
Table 91. C.B. Fleet Company Details
Table 92. C.B. Fleet Business Overview
Table 93. C.B. Fleet Opioid-induced Constipation Product
Table 94. C.B. Fleet Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 95. C.B. Fleet Recent Development
Table 96. Cosmo Pharmaceuticals Company Details
Table 97. Cosmo Pharmaceuticals Business Overview
Table 98. Cosmo Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 99. Cosmo Pharmaceuticals Recent Development
Table 100. Daewoong Company Details
Table 101. Daewoong Business Overview
Table 102. Daewoong Opioid-induced Constipation Product
Table 103. Daewoong Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 104. Daewoong Recent Development
Table 105. Daiichi Sankyo Company Details
Table 106. Daiichi Sankyo Business Overview
Table 107. Daiichi Sankyo Opioid-induced Constipation Product
Table 108. Daiichi Sankyo Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 109. Daiichi Sankyo Recent Development
Table 110. GlaxoSmithKline Company Details
Table 111. GlaxoSmithKline Business Overview
Table 112. GlaxoSmithKline Opioid-induced Constipation Product
Table 113. GlaxoSmithKline Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 114. GlaxoSmithKline Recent Development
Table 115. Ironwood Pharmaceuticals Company Details
Table 116. Ironwood Pharmaceuticals Business Overview
Table 117. Ironwood Pharmaceuticals Opioid-induced Constipation Product
Table 118. Ironwood Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 119. Ironwood Pharmaceuticals Recent Development
Table 120. Johnson and Johnson Company Details
Table 121. Johnson and Johnson Business Overview
Table 122. Johnson and Johnson Opioid-induced Constipation Product
Table 123. Johnson and Johnson Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 124. Johnson and Johnson Recent Development
Table 125. Merck Company Details
Table 126. Merck Business Overview
Table 127. Merck Opioid-induced Constipation Product
Table 128. Merck Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 129. Merck Recent Development
Table 130. Mundipharma Company Details
Table 131. Mundipharma Business Overview
Table 132. Mundipharma Opioid-induced Constipation Product
Table 133. Mundipharma Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 134. Mundipharma Recent Development
Table 135. Nektar Therapeutics Company Details
Table 136. Nektar Therapeutics Business Overview
Table 137. Nektar Therapeutics Opioid-induced Constipation Product
Table 138. Nektar Therapeutics Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 139. Nektar Therapeutics Recent Development
Table 140. Pfizer Company Details
Table 141. Pfizer Business Overview
Table 142. Pfizer Opioid-induced Constipation Product
Table 143. Pfizer Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 144. Pfizer Recent Development
Table 145. Progenics Pharmaceuticals Company Details
Table 146. Progenics Pharmaceuticals Business Overview
Table 147. Progenics Pharmaceuticals Opioid-induced Constipation Product
Table 148. Progenics Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 149. Progenics Pharmaceuticals Recent Development
Table 150. Shionogi Company Details
Table 151. Shionogi Business Overview
Table 152. Shionogi Opioid-induced Constipation Product
Table 153. Shionogi Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 154. Shionogi Recent Development
Table 155. SLA Pharma Company Details
Table 156. SLA Pharma Business Overview
Table 157. SLA Pharma Opioid-induced Constipation Product
Table 158. SLA Pharma Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 159. SLA Pharma Recent Development
Table 160. Sucampo Company Details
Table 161. Sucampo Business Overview
Table 162. Sucampo Opioid-induced Constipation Product
Table 163. Sucampo Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 164. Sucampo Recent Development
Table 165. Synergy Pharmaceuticals Company Details
Table 166. Synergy Pharmaceuticals Business Overview
Table 167. Synergy Pharmaceuticals Opioid-induced Constipation Product
Table 168. Synergy Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 169. Synergy Pharmaceuticals Recent Development
Table 170. Theravance Company Details
Table 171. Theravance Business Overview
Table 172. Theravance Opioid-induced Constipation Product
Table 173. Theravance Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million)
Table 174. Theravance Recent Development
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Opioid-induced Constipation Market Share by Type: 2020 VS 2027
Figure 2. Solid Features
Figure 3. Liquid Features
Figure 4. Global Opioid-induced Constipation Market Share by Application: 2020 VS 2027
Figure 5. Drugstore Case Studies
Figure 6. Hospital Case Studies
Figure 7. Others Case Studies
Figure 8. Opioid-induced Constipation Report Years Considered
Figure 9. Global Opioid-induced Constipation Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Opioid-induced Constipation Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Opioid-induced Constipation Market Share by Regions: 2020 VS 2027
Figure 12. Global Opioid-induced Constipation Market Share by Regions (2022-2027)
Figure 13. Global Opioid-induced Constipation Market Share by Players in 2020
Figure 14. Global Top Opioid-induced Constipation Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-induced Constipation as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Opioid-induced Constipation Revenue in 2020
Figure 16. Global Opioid-induced Constipation Revenue Market Share by Type (2016-2021)
Figure 17. Global Opioid-induced Constipation Revenue Market Share by Type (2022-2027)
Figure 18. North America Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Opioid-induced Constipation Market Share by Type (2016-2027)
Figure 20. North America Opioid-induced Constipation Market Share by Application (2016-2027)
Figure 21. North America Opioid-induced Constipation Market Share by Country (2016-2027)
Figure 22. United States Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Opioid-induced Constipation Market Share by Type (2016-2027)
Figure 26. Europe Opioid-induced Constipation Market Share by Application (2016-2027)
Figure 27. Europe Opioid-induced Constipation Market Share by Country (2016-2027)
Figure 28. Germany Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Opioid-induced Constipation Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Opioid-induced Constipation Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Opioid-induced Constipation Market Share by Region (2016-2027)
Figure 38. China Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Opioid-induced Constipation Market Share by Type (2016-2027)
Figure 46. Latin America Opioid-induced Constipation Market Share by Application (2016-2027)
Figure 47. Latin America Opioid-induced Constipation Market Share by Country (2016-2027)
Figure 48. Mexico Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Opioid-induced Constipation Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Opioid-induced Constipation Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Opioid-induced Constipation Market Share by Country (2016-2027)
Figure 54. Turkey Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. AstraZeneca Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 58. Takeda Pharmaceutical Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 59. Bausch Health Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 60. Abbott Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 61. Bayer Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 62. Boehringer Ingelheim Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 63. C.B. Fleet Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 64. Cosmo Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 65. Daewoong Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 66. Daiichi Sankyo Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 68. Ironwood Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 69. Johnson and Johnson Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 70. Merck Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 71. Mundipharma Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 72. Nektar Therapeutics Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 73. Pfizer Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 74. Progenics Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 75. Shionogi Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 76. SLA Pharma Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 77. Sucampo Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 78. Synergy Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 79. Theravance Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[オピオイド誘発性便秘の世界市場規模・現状・予測2021年-2027年] (Global Opioid-induced Constipation Market Size, Status and Forecast 2021-2027 / QY21APR4282)についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆